Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.

Efforts Ongoing to Move Biosimilars Into Mainstream Cancer Care

September 6th 2019

Lee S. Schwartzberg, MD, discusses the mission of OneOncology as well as the work that is being done to bring biosimilars to the market.

Signs Point to Better Market Conditions for Biosimilars

September 5th 2019

Even though many challenges must be overcome before widespread adoption can occur, there is still much promise on the horizon for biosimilars.

Dr. Kolberg on Collecting Real-World Biosimilar Trastuzumab Data in Breast Cancer

September 4th 2019

Hans-Christian Kolberg, MD, discusses collecting real-world data for biosimilars, specifically the trastuzumab biosimilar ABP 980 for breast cancer.

Dr. Welslau on Financial Savings of Biosimilar Rituximab in DLBCL

August 30th 2019

Manfred Welslau, MD, discusses financial savings of using a rituximab biosimilar for patients with previously untreated CD20-positive diffuse large B-cell lymphoma.

Efficacy, Education, and Cost-Effectiveness Mark Latest Biosimilar Developments

August 30th 2019

A cluster of clinical news in biosimilars has been announced over the last few days, with pooled data sets against reference products, an expected launch of a novel study, and a cost efficiency analysis.

Dr. Lyman on Educating Physicians About Biosimilars in Oncology

August 30th 2019

Gary H. Lyman, MD, MPH, discusses educating physicians about biosimilars in oncology.

Dr. Kolberg on the Safety Profile of Trastuzumab Biosimilars in Breast Cancer

August 30th 2019

Hans-Christian Kolberg, MD, discusses cost reduction and safety of biosimilars, specifically ones for trastuzumab biosimilars in breast cancer.

Biosimilar Education Critical to Accelerating Integration Into Standard Oncology Practice

August 29th 2019

Robert M. Rifkin, MD, FACP, discusses details of bringing biosimilars to market, ongoing challenges, and the need for education of these products.

Dr. Leon Ferre on Reasons to Explore Biosimilars in Oncology

August 29th 2019

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses reasons to explore biosimilars in oncology.

Dr. Bardia Discusses the Skepticism Regarding Biosimilars in Oncology

August 28th 2019

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, and assistant professor of medicine, Harvard Medical School, discusses the skepticism regarding biosimilars in oncology.

Dr. Domchek on Potential Benefits of Biosimilars in Oncology

August 28th 2019

Susan Domchek, MD, director, MacDonald Women’s Cancer Risk Evaluation Center, executive director, the Basser Center for BRCA, and Basser Professor in Oncology, at Penn Medicine, discusses the potential benefits of biosimilars in oncology.

Dr. Litton Discusses the Potential Advantage of Using Biosimilars in Oncology

August 28th 2019

Jennifer K. Litton, MD, associate professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the potential advantage of using biosimilars in oncology.

Dr. Welslau on Acceptance of Rituximab Biosimilar in DLBCL

August 28th 2019

Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the growing acceptance of a rituximab (Rituxan) biosimilar in the treatment of patients with diffuse large B-cell lymphoma, following favorable results from a safety analysis of the REFLECT study.

Dr. Martin on Provider Confidence With Biosimilars in Oncology

August 23rd 2019

Miguel Martín, MD, PhD, professor of medicine at the Complutense University, and head of the Medical Oncology Service at the Hospital General Universitario Gregorio Marañon in Madrid, Spain, discusses provider confidence with biosimilars in oncology.

Dr. Esteva on the Future of Biosimilars in Breast Cancer

August 23rd 2019

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States.

New Developments Propel Biosimilar Penetration of US Oncology Market

August 23rd 2019

The biosimilars realm of oncology has been surrounded by a burst of clinical and regulatory news this week, with the read out of phase III findings and extension data, legality issues, and more.

Dr. Hurvitz on the Potential Global Impact of Biosimilars in Breast Cancer

August 23rd 2019

Sara Hurvitz, MD, associate professor, David Geffen School of Medicine, UCLA; medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit; co-director, Santa Monica-UCLA Outpatient Oncology Practices; and director, Breast Cancer Clinical Trials Program, UCLA, discusses the potential global impact of biosimilars in breast cancer.

Rituximab Biosimilar Shows Equivalency in CD20+ Non-Hodgkin Lymphoma

August 23rd 2019

ABP 798, a rituximab (Rituxan) biosimilar, demonstrated clinical equivalency to reference rituximab in patients with CD20-positive B-cell non-Hodgkin lymphoma.

Trastuzumab Biosimilar Efficacy Sustained With Updated Data

August 22nd 2019

Adjuvant treatment with the trastuzumab biosimilar CT-P6 demonstrated comparable efficacy and safety to the reference product in patients with HER2-positive early breast cancer.

Dr. Schmid on the Role of Biosimilars in Oncology

August 20th 2019

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the role of biosimilars in oncology.